Building the next category-defining molecular diagnostics platform.
Kihealth is developing a scalable molecular diagnostics platform positioned at the intersection of precision medicine, preventative healthcare, metabolic disease, and AI-driven biomarker intelligence.
A generational market. A single molecular platform built to serve it.
Kihealth is positioned at the intersection of the world's largest and fastest-growing chronic disease markets — with a scalable platform designed to compound advantage across every vertical it enters.
One molecular intelligence platform — powering an expanding portfolio of disease-interception diagnostics.
A precision diagnostics company built on one molecular intelligence platform.
Kihealth Labs is a clinical-stage molecular diagnostics company operating a high-complexity CLIA laboratory and advancing a multi-disease pipeline on the InterceptIQ™ platform.
One Platform. Every Layer of Disease Interception.
Intercept IQ is Kihealth's scalable molecular intelligence platform. Each diagnostic application shares the same scientific infrastructure — enabling faster development, lower incremental costs, and expansion into additional disease areas over time.
Every diagnostic, built on the same molecular intelligence core.
Each product below is an extension of the Intercept IQ platform — not a separate one-off assay. New diseases. Same engine.
Early autoimmune beta-cell injury detection for earlier identification, monitoring, and intervention in Type 1 diabetes.
Early cancer detection beginning with pancreatic cancer, with a growing future oncology pipeline.
Beta-cell dysfunction detection and GLP-1 therapy monitoring across metabolic disease and Type 2 diabetes.
Alzheimer's disease and broader CNS biomarker detection — future neurodegenerative applications.
One platform. Every layer of disease interception.
Hover any layer to follow the flow of molecular data through the InterceptIQ™ platform.
A single blood draw enters the platform.
CLIA-grade workflows preserve picogram-level molecular signals.
Multi-task models calibrated against clinical ground truth.
The unified intelligence layer powering every Kihealth product.
Translating molecular intelligence into outcomes at every scale.
A repeatable scientific pipeline turning molecular discoveries into clinically validated diagnostics.
From Biomarker Discovery to Clinical Launch.
A repeatable five-stage pipeline that turns molecular discoveries into clinically validated diagnostics. Every product Kihealth builds moves through the same scientific infrastructure — compounding speed, evidence, and capital efficiency with each launch.
Biomarker Discovery
Identify novel molecular biomarkers associated with disease onset and progression using whole-genome methylation and fragmentomic profiling.
- Timeline
- 1–2 Years
- Research Samples
- 100–300 Samples
Biomarker Validation
Confirm biomarker reproducibility and biological significance across independent patient cohorts before advancing into assay development.
- Timeline
- 6–12 Months
- Validation Cohort
- 300–500 Samples
Assay Development
Develop and analytically validate a robust molecular assay — including ddPCR and targeted NGS workflows — suitable for clinical use.
- Timeline
- ~6 Months
- Output
- Clinical-grade assay
Clinical Validation
Demonstrate analytical performance and clinical utility across diverse patient populations under CLIA / CAP standards.
- Timeline
- 12–24 Months
- Clinical Samples
- 500–1,500 Patients
Clinical Launch
Deploy validated assays through Kihealth's CLIA-certified laboratory and commercial partnerships for real-world patient impact.
- Timeline
- 6–12 Months
- Commercial Validation
- 1,000+ Clinical Samples
Every assay runs on the same scientific infrastructure — Intercept IQ.
Each new program reuses chemistry, automation, and AI — reducing incremental cost.
Diabetes, oncology, and neurodegeneration today. New indications tomorrow.
One platform. A pipeline of products. Decades of compounding value.
Building a Platform Company — Not a Single-Product Company.
Traditional diagnostics companies rely on a single assay and a single market. Kihealth is building a scalable molecular intelligence platform capable of producing multiple diagnostics across metabolic disease, oncology, neuroscience, and future therapeutic areas. Investors are backing a platform that can continuously generate new products — not a single commercial opportunity.
Platform Advantage
Every future diagnostic leverages the same molecular intelligence platform — accelerating speed-to-market and compounding clinical performance.
Scalable Economics
New products become faster and less expensive to develop as the platform expands — each indication amortizes shared R&D investment.
Shared Clinical Infrastructure
Lab, bioinformatics, clinical ops, regulatory, commercial, and AI support every vertical simultaneously.
Expanding Data Moat
Every patient strengthens the platform through proprietary longitudinal molecular datasets — network effects in clinical truth.
Multiple Revenue Streams
Clinical diagnostics, research, clinical trials, pharma partnerships, companion Dx, population screening, employer programs, licensing, international, AI software.
Capital Efficient Expansion
Each new disease indication expands value without rebuilding infrastructure — capital efficiency that traditional diagnostics companies cannot match.
Engineered for clinical scale, regulatory rigor, and commercial reach.
From Core Platform to Commercial Applications.
A purpose-built technology stack engineered for scale — regulatory, payer, and enterprise-ready from day one. The same Intercept IQ core feeds every clinical, commercial, and pharma application above it.
Applications
InterceptIQ™ AI Platform
Proprietary Data & Technology
Patient & Healthcare System
One of the largest opportunities in modern healthcare.
Every InterceptIQ™ vertical attaches the platform to a multi-billion-dollar market — and every Kihealth company multiplies the addressable opportunity.
The macro tailwinds
behind the platform.
Kihealth sits at the intersection of the largest, fastest-growing forces in modern medicine — precision diagnostics, GLP-1 expansion, the global diabetes epidemic, and the shift from reactive care to prediction and prevention.
Precision medicine is the fastest-growing segment of healthcare.
Individualized, molecular-driven care is replacing one-size-fits-all treatment paradigms. Payers, providers, and patients are aligning around biomarker-driven decision making.
GLP-1s are reshaping metabolic care at unprecedented scale.
Tens of millions of new patients are entering long-term GLP-1 therapy. Companion diagnostics and longitudinal beta-cell monitoring become increasingly valuable as therapy selection, response, and durability drive outcomes.
Diabetes is on track to affect 800M+ people globally by 2050.
Diabetes is one of the fastest-expanding chronic conditions worldwide — driving trillions in downstream cost. Earlier detection at the beta-cell level fundamentally changes outcomes and economics.
Healthcare is shifting from reactive treatment to prediction and prevention.
Value-based care, employer risk pools, and payer economics are all realigning around predicting disease early and intervening before irreversible damage. Molecular monitoring is the technology enabler.
A platform at the convergence of every major healthcare megatrend.
Kihealth is building a diagnostics platform positioned at the intersection of the forces reshaping medicine — creating a uniquely attractive opportunity to build a category-defining company against one of the largest unmet needs in healthcare.
Earlier detection. Better decisions. Improved outcomes — at scale.
From reactive cost center to predictive value engine.
Healthcare's largest cost burdens come from late-stage disease. InterceptIQ™ shifts the economics — predicting and preventing disease before it becomes the system's biggest expense.
Reactive Medicine
- 01Reactive Medicine
- 02Symptom-Based Care
- 03Laboratory Confirmation
- 04Treatment
InterceptIQ™
- 01InterceptIQ™
- 02Continuous Molecular Monitoring
- 03AI Prediction
- 04Risk Stratification
- 05Earlier Intervention
- 06Prevention
- 07Improved Outcomes
One platform. Multiple high-value verticals.
Every company expands the addressable market.
The Kihealth ecosystem transforms a single core diagnostic platform into multiple high-value, disease-specific businesses. Each portfolio company expands the commercial opportunity, strengthens the proprietary data network, and increases the long-term value of the overall platform — creating multiple paths to growth while leveraging the same underlying technology.
One platform.
Multiple diseases.
Global impact.
Today
Tomorrow
Building the operating system for the future of precision healthcare.
Request the corporate overview or speak with our investor relations team.
Kihealth is a privately held company. This page contains forward-looking statements regarding our platform, pipeline, regulatory plans, and financing activities. Actual results may differ materially.